Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 12.
doi: 10.4103/sjg.sjg_169_25. Online ahead of print.

Patterns and predictors of biologic therapy switching in inflammatory bowel disease at a tertiary care center: A retrospective observational study

Ahmed G Alghamdi  1   2 , Hadeel S Aldofaian  1 , Mohammed S Alahmari  1 , Bashaar K Alibrahim  1 , Mishal A Alshowair  1 , Hussam A Alhamidi  1 , Abdullah H Bawazir  3 , Amal M Aseri  3 , Alaa A Aldeibani  3 , Mohanned M AlRaddadi  3 , Reem O Almutairi  3 , Sultan S Alshahrani  3 , Abdullah D Alenezi  4 , Rakan H Alshala  5 , Abeer M Alhuraibi  1 , Renad M Alharbi  1
Affiliations
Free article

Patterns and predictors of biologic therapy switching in inflammatory bowel disease at a tertiary care center: A retrospective observational study

Ahmed G Alghamdi et al. Saudi J Gastroenterol. .
Free article

Abstract

Background: Approximately one-third of inflammatory bowel disease (IBD) patients fail to respond to anti-tumor necrosis factor (anti-TNF) therapy, presenting a significant challenge. The two management strategies are changing to a second anti-TNF agent or a drug with a different mechanism of action.

Methods: A retrospective study was conducted on patients with IBD who initiated biologic therapy, between January 2016 and July 2024. Data were extracted from the records of King Fahad Medical City (KFMC). Categorical data were presented as frequencies and percentages. The χ² test was used to evaluate the association between the choice of first, second, and third biologics with C.D. and U.C. Multivariable hazard ratios (HRs) were calculated to identify predictors of drug change. Kaplan-Meier curves were used to compare time to biological change, stratified by disease type.

Results: The study included 607 Crohn's disease (CD) and 392 ulcerative colitis (UC) patients. Most CD patients were male (56.3%), aged 31-45 (45.5% years), with ileocolonic disease (64.9%), and with a penetrating phenotype (38.6%). UC predominantly affected females (55.6%) aged 31-45 (44.4% years), with extensive colitis (63.3%). Infliximab was the most used biologic, with median persistence times of 69 months (CD) and 47 months (UC). In CD, Infliximab is commonly switched to Adalimumab and Ustekinumab. In UC, Infliximab was primarily switched to Ustekinumab, Adalimumab, and Vedolizumab. Persistence times varied; in CD patients treated with Infliximab, persistence was longer before switching compared with those treated with Adalimumab (P = 0.007). In UC, Infliximab persistence (47 months) exceeded that of Adalimumab (23 months; P = 0.016). Regression analysis identified key predictors of switching. In CD, a family history of IBD significantly increased the risk (HR = 1.46, 95% CI: 1.01-2.10; P = 0.042). In UC, younger age (18-30 years) increased risk (HR = 5.94, 95% CI: 1.09-32.27; P = 0.039), while being single reduced it (HR = 0.50, 95% CI: 0.28-0.89; P = 0.019).

Conclusion: Anti-TNF therapies remain the first- and second-line biologics. Non-anti-TNF agents (Vedolizumab and Ustekinumab) are mainly employed as third-line options for IBD patients.

Keywords: Crohn’s disease; inflammatory bowel disease; primary failure; treatment patterns; ulcerative colitis.

PubMed Disclaimer

References

    1. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis 2017;11:3–25.
    1. Atreya R, Neurath MF, Siegmund B. Personalizing treatment in IBD: Hype or reality in 2020? Can we predict response to anti-TNF?. Front Med (Lausanne) 2020;7:517.
    1. Eder P, Katulska K, Lykowska-Szuber L, Stawczyk-Eder K, Krela-Kaźmierczak I, Klimczak K, et al. Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies. Sci Rep 2015;5:10223.
    1. Sochał M, Krzywdzińska M, Gabryel M, Małecka-Panas E, Cichoż-Lach H, Garlicki A, et al. A simple index to predict the efficiency of adalimumab treatment in Crohn's disease with a limited duration of therapy. Pol Arch Intern Med 2020;130:524–31.
    1. Stidham RW, Lee TC, Higgins PDR, Deshpande AR, Sussman DA, Singal AG, et al. Systematic review with network meta-analysis: The efficacy of anti-TNF agents for the treatment of Crohn's disease. Aliment Pharmacol Ther 2014;39:1349–62.

LinkOut - more resources